Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Relay Therapeutics (RLAY)
NASDAQ:RLAY
RESEARCH TOOLSreports
RLAY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.50 - $11.02
Previous CloseN/A
Volume391.09K
Average Volume (3M)2.33M
Market Cap
$656.14M
Enterprise Value$203.03M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Feb 20, 2025EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.61
Shares Outstanding167,382,970
10 Day Avg. Volume1,306,345
30 Day Avg. Volume2,334,849
Standard Deviation0.18
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)65.57
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.01
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$18.17Price Target Upside344.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Relay Therapeutics News
PremiumCompany Announcements
Relay Therapeutics Highlights Progress at Healthcare Conference
PremiumCompany Announcements
Relay Therapeutics Reports Promising Data on RLY-2608
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe fast initial responses seen in RLY-2608 monotherapy and fulvestrant combo are considered a positive surprise in the updated data.
Corporate StrategyThere is confidence in Relay Therapeutics' strategy of running smart trials with strong partners, which is seen as a key factor in the company's potential success.
Market ValuationCurrent share price presents a valuation disconnect and an opportunity for RLAY with a $230M EV ($790M MC), underscoring the potential of RLY-2608.
Bears Say
CompetitionIn Lilly's hands, STX-478 is a more significant threat, in our view.
Market CompetitionDespite differences in trial data, STX-478's early data is considered in line with Relay Therapeutics' data, which is viewed positively for the company's competitive position.
Strategic ConcernsKey questions remain about RLAY's ability to adapt to a shifting treatment landscape and combination partners in 2L mBC.
---
Ownership Overview
2.95% Insiders
19.29% Mutual Funds
49.01% Other Institutional Investors
13.22% Public Companies and Individual Investors
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $3.50 and its highest was $11.02 in the past 12 months.
What is Relay Therapeutics’s market cap?
Relay Therapeutics’s market cap is $656.14M.
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is yesterday.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.772 by $0.142.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -0.59.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 167,382,970 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.772. Following the earnings report the stock price went down -1.76%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Currently, no hedge funds are holding shares in RLAY
---
Relay Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.17 (344.25% Upside)
$18.17 (344.25% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.62%
12-Months-Change
Fundamentals
Return on Equity
-42.69%
Trailing 12-Months
Asset Growth
2.55%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.
---
RLAY Stock 12 Month Forecast
Average Price Target
$18.17
▲(344.25% Upside)
Technical Analysis
Best Analysts Covering RLAY
1 Year
1 Year Success Rate
0/20 ratings generated profit
1 Year Average Return
-35.59%
reiterated a buy rating last month
Copying Robert Burns's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -35.59% per trade.
---